Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Fish at the Podium

IP Chat Channel Webinar "Divided Infringement in the Life Sciences: Implications of Limelight v. Akamai"

Thursday, August 7th, 2014, 2:00 pm EDT

Fish at the Podium

IP Chat Channel Webinar "Divided Infringement in the Life Sciences: Implications of Limelight v. Akamai"

Thursday, August 7th, 2014, 2:00 pm EDT

Back to Events Listing

On Thursday, August 7th, Fish Principal Jonathan Singer (Twin Cities) will speak on “Divided Infringement in the Life Sciences: Implications of Limelight v. Akamai” during an IP Chat Channel webinar. Please see below or visit the event website for more details.

Divided Infringement in the Life Sciences: Implications of Limelight v. Akamai
Thursday, August 7 at 2:00pm ET

The life sciences industry must attend closely to legal issues surrounding divided infringement. Traditional method of treatment claims — even a simple claim directed to a “method of treating disease X comprising administering drug Y to a patient in need thereof,” — may require multiple actors to infringe, including a physician to diagnose the disease and write a prescription, a pharmacist to fill the prescription, and a patient or another healthcare provider to administer the drug. More complicated situations involve therapy claims using a combination of drugs or method claims that require a doctor to determine whether a particular marker is present or absent in a biological tissue before writing a prescription or administering a drug.

This webinar will examine the impact of the U.S. Supreme Court’s recent opinion in Limelight v. Akamai on the life sciences. That decision rejected the U.S. Court of Appeals for the Federal Circuit’s attempt to change the definition of inducement to include actions by multiple players, while leaving the door open to a solution to the challenge of divided infringement within the rubric of direct infringement.

Our panel includes a life-sciences IP strategist, a leading life-sciences litigator, and a senior patent counsel for a major pharmaceutical company. They will discuss:
•Patent prosecution strategies for dealing with joint infringement issues,
•How litigation involving joint infringement in the life sciences is likely to play out, and
•How joint infringement uncertainties are likely to affect licensing other life science transactions.

Speakers:
•Ned Israelsen, Knobbe, Martens, Olson & Bear, LLP
•Jonathan Singer, Fish & Richardson, PC
•Mark Stewart, Eli Lilly and Co.

 

Stay current with Fish Sign up for our Newsletter